Welcome to our dedicated page for BioXcel Therapeutics SEC filings (Ticker: BTAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioXcel Therapeutics filings document regulatory, financing, governance, and operating disclosures for a Nasdaq-listed biopharmaceutical company focused on AI-supported drug re-innovation in neuroscience. The company’s Form 8-K reports include IGALMI regulatory updates, business and financial results, and exhibits tied to press releases and material corporate events.
The filing record also covers registered direct offerings, common stock, pre-funded warrants and accompanying warrants, credit agreement amendments, registration rights, unregistered equity issuances, and retention or milestone-based compensation arrangements. These disclosures describe BioXcel’s capital structure, contractual obligations, Nasdaq-listed common stock, and formal updates connected to its approved IGALMI product and BXCL501 development program.
BioXcel Therapeutics, Inc. submitted a Form 144 notice relating to a proposed sale of 6,560 shares of Common Stock. The shares are tied to the vesting of restricted stock unit awards dated 05/04/2026 and were granted as part of issuer equity compensation plan.
BioXcel Therapeutics, Inc. submitted a Rule 144 notice to sell 6,845 shares of Common Stock related to restricted stock units that vested on 05/04/2026.
The filing lists 30,877,605 shares outstanding as of 05/20/2026 and identifies the sale as tied to the vesting of RSU awards granted under the issuer's equity compensation plan.
BioXcel Therapeutics filed a Form 144 reporting the vesting and proposed sale of 6,845 shares of Common Stock. The securities are described as restricted stock unit awards that vested on 05/04/2026. The filing shows 30,877,605 shares outstanding as of 05/20/2026 on NASDAQ.
BioXcel Therapeutics reports that Armistice Capital, LLC and Steven Boyd beneficially own 1,910,076 shares of common stock, representing 7.05% of the class. The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., shares voting and dispositive power over those shares.
The statement is a Schedule 13G style disclosure identifying beneficial ownership and the reporting persons; it notes the Master Fund holds the shares and that the Master Fund has the right to receive dividends or sale proceeds. The filing is signed by Steven Boyd on 05/15/2026.
BioXcel Therapeutics reported first quarter 2026 results and a key regulatory milestone. The FDA accepted a supplemental New Drug Application for IGALMI for at-home use in agitation tied to bipolar disorders or schizophrenia and set a November 14, 2026 PDUFA action date. The company is also advancing BXCL501 in late-stage trials for agitation in Alzheimer’s dementia and is evaluating strategic options with an advisor for the IGALMI franchise.
Net revenue from IGALMI was $206 (thousands) versus $168 (thousands) a year earlier. Operating expenses were $10,429 (thousands), driven mainly by $7,191 (thousands) in SG&A and $2,955 (thousands) in R&D, leading to a net loss of $12,691 (thousands), compared with $7,254 (thousands) in 2025. Cash, cash equivalents and restricted cash were $17,180 (thousands) as of March 31, 2026, and total stockholders’ equity was a deficit of $105,543 (thousands). The company notes conditions and events that raise substantial doubt about its ability to continue as a going concern.
BioXcel Therapeutics reported first-quarter 2026 product revenue of $206 thousand, with a net loss of $12,691 thousand and operating cash outflow of $11,809 thousand. Cash and cash equivalents were $17,180 thousand, against total debt of $100,289 thousand and total liabilities of $139,568 thousand.
The company’s accumulated deficit reached $732,785 thousand and stockholders’ deficit widened to $105,543 thousand. Management concludes there is substantial doubt about BioXcel’s ability to continue as a going concern, despite multiple equity financings, warrant repricings and repeated amendments and waivers under its Oaktree-led credit facility.
BioXcel Therapeutics, Inc. director and CEO Vimal Mehta reported equity changes related to previously granted restricted stock units. He exercised 18,000 Restricted Stock Units into 18,000 shares of Common Stock at a stated price of $0.0000 per share, increasing his direct Common Stock holdings to 39,259 shares.
The filing also shows indirect ownership of 480,343 Common Stock shares held by BioXcel LLC and 125 shares held by his spouse. A prior grant of 18,000 RSUs on August 1, 2025 was scheduled to vest in full within 30 days of nine months from that grant date, subject to continued employment.
BioXcel Therapeutics, Inc. Chief Financial Officer Richard I. Steinhart exercised 9,000 Restricted Stock Units into Common Stock. The RSUs, each representing one share of common stock, were granted on August 1, 2025 and vested in full approximately nine months after the grant date, contingent on continued employment. Following this compensation-related conversion, Steinhart directly holds 15,645 shares of BioXcel Therapeutics common stock.
BioXcel Therapeutics, Inc. Chief Scientific Officer Frank Yocca exercised 9,000 Restricted Stock Units into shares of Common Stock on May 1, 2026. The RSUs were granted on August 1, 2025 and represented a right to receive one share of common stock per unit.
Following this vesting and conversion, Yocca directly holds 15,520 shares of BioXcel common stock. The RSU award vested in full approximately nine months after the grant date, contingent on his continued employment with the company.
BioXcel Therapeutics, Inc. officer Javier Rodriguez exercised 9,000 Restricted Stock Units into Common Stock on May 1, 2026. Each RSU converted into one share at a price of $0.00 per share, increasing his direct holdings to 15,863 Common Stock shares.
The 9,000 RSUs were granted on August 1, 2025 and were scheduled to vest in full approximately nine months after the grant date, contingent on continued employment. Following this vesting and conversion, no RSUs from this grant remain outstanding.